<code id='D7DBB7B973'></code><style id='D7DBB7B973'></style>
    • <acronym id='D7DBB7B973'></acronym>
      <center id='D7DBB7B973'><center id='D7DBB7B973'><tfoot id='D7DBB7B973'></tfoot></center><abbr id='D7DBB7B973'><dir id='D7DBB7B973'><tfoot id='D7DBB7B973'></tfoot><noframes id='D7DBB7B973'>

    • <optgroup id='D7DBB7B973'><strike id='D7DBB7B973'><sup id='D7DBB7B973'></sup></strike><code id='D7DBB7B973'></code></optgroup>
        1. <b id='D7DBB7B973'><label id='D7DBB7B973'><select id='D7DBB7B973'><dt id='D7DBB7B973'><span id='D7DBB7B973'></span></dt></select></label></b><u id='D7DBB7B973'></u>
          <i id='D7DBB7B973'><strike id='D7DBB7B973'><tt id='D7DBB7B973'><pre id='D7DBB7B973'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:3
          Adobe

          Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

          Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

          advertisement

          Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Novo acquires Inversago for up to $1 billion
          Novo acquires Inversago for up to $1 billion

          LISELOTTESABROE/Scanpix/AFPviaGettyImagesFreshoffofthenewsthatitsdrugWegovymaynotjusthelppeoplelosew

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Venture capital firm's plans to take over Akron hospital face hurdles

          SummaHealthGeneralCatalysts’sgrandvisionforaventurecapital-ownedhospitalsystemseamlesslyblendingAIan